What is the evidence that blood-brain barrier (BBB) permeability changes serve as early biomarkers for neurodegeneration?
Focus areas:
- CSF biomarker panels for BBB dysfunction (tight junction proteins like claudin-5, zonula occludens-1; pericyte markers like PDGFR-beta)
- Blood-based BBB permeability indicators (S100B, NFL, GFAP in plasma vs CSF)
- Dynamic contrast-enhanced MRI measures of BBB leakage as early AD/PD markers
- Relationship between BBB disruption and neurovascular uncoupling preceding motor/cognitive symptoms
- Comparative utility of BBB permeability markers vs amyloid/tau PET for early detection
A LASSO-optimized composite score integrating plasma GFAP, S100B, NFL, soluble PDGFR-β, and claudin-5 fragments to achieve AUC >0.90 for pre-symptomatic AD/PD, outperforming single-marker approaches including amyloid PET.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["Astrocyte End-Foot GFAP Network Perivascular Cytoskeleton"]
B["AQP4 Polarization and Claudin-5 Support BBB Interface Integrity"]
C["Stress-Driven GFAP Redistribution End-foot to Soma Shift"]
D["Barrier Support Failure Neurovascular Coupling Weakens"]
E["Plasma GFAP/S100B Rise Early BBB Dysfunction Readout"]
F["Pre-symptomatic Neurodegeneration Signal Astrovascular Injury Window"]
A --> B
C -.->|"disrupts"| B
B --> F
C --> D
D --> E
E --> F
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style D fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#1b5e20,stroke:#81c784,color:#81c784
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
5 citations5 with PMID5 mediumValidation: 0%5 supporting / 0 opposing
✓For(5)
5
No opposing evidence
(0)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
3
2
MECH 0CLIN 3GENE 2EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Plasma NfL, GFAP, amyloid, and p-tau species as Pr…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
No debate transcripts available for this hypothesis.